A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.
Epistemonikos ID: 667181312b3deb42035eae9851edf0190d6d0a47
First added on: May 07, 2024